From the Journals

Targeting obesity could slow brain aging in psychosis


 

FROM THE JOURNAL OF PSYCHIATRIC RESEARCH


A psychiatrist used the Mini-International Neuropsychiatric Interview and the Positive and Negative Syndrome Scale to determine diagnostic assessments and symptom ratings. Several CV risk factors were measured, including blood pressure, triglycerides, HDL, and LDL. Using the charts, the researchers verified the absence of diabetes by fasting glucose. They also checked participants’ BMI and height.

Doctors review brain scans ©Jochen Sand/Thinkstock
Through the use of MRI, participants’ brains were scanned, and their brain age was estimated via the BrainAGE score. This is calculated as the difference between estimated brain age and chronological age (Neuroimage. 2010. 50[3]:883-92).

“This study suggests that overweight/obesity, which is frequent in schizophrenia, may contribute to neurostructural changes already early in the course of illness,” the investigators wrote. “Specifically, the brains of participants with FEP appeared on average 2.64 years older than their chronological age.”

Among participants with both FEP and overweight/obesity, the investigators found the average discrepancy between brain and chronological age to be as high as 3.83 years.

They cited several limitations. Because the study was not prospective, the researchers could not establish causality of the association between metabolic alterations and brain structure. In addition, the existence of insulin resistance could not be ruled out – although none of the participants reported a history of type 2 diabetes.

Still, “the results were robust, persisted in subgroup analyses, and replicated many of the previously reported findings,” the investigators wrote.

They reported no conflicts of interest.

ghenderson@mdedge.com

SOURCE: Kolenic M et al. J Psychiatric Res. 2018 Apr. 99:151-8.

Pages

Recommended Reading

Antipsychotics linked to sudden cardiac death risk
MDedge Cardiology
Psychiatrists' role in CVD risk management growing
MDedge Cardiology
Schizophrenia linked with dyslipidemia, hypertension, and smoking
MDedge Cardiology
Schizophrenia patients twice as likely to be at risk for DVT and PE
MDedge Cardiology
Researchers highlight gaps in diabetes screening in patients on antipsychotics
MDedge Cardiology
Antipsychotics may double to triple diabetes risk in youth
MDedge Cardiology
Prepsychosis links with elevated metabolic syndrome
MDedge Cardiology
Statement warns of drugs causing or exacerbating heart failure
MDedge Cardiology
Liraglutide produced cardiometabolic benefits in patients with schizophrenia
MDedge Cardiology
Watch for QTc interval prolongation in patients taking antipsychotics
MDedge Cardiology